Satake Tomoyuki, Shibuki Taro, Watanabe Kazuo, Sasaki Mitsuhito, Imaoka Hiroshi, Mitsunaga Shuichi, Kojima Motohiro, Ikeda Masafumi
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan.
Front Oncol. 2023 Jul 21;13:1234113. doi: 10.3389/fonc.2023.1234113. eCollection 2023.
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver cancers. Therapeutic strategies for patients with cHCC-CCA are limited, and no standard systemic treatment has been established for unresectable cHCC-CCA. Here, we present six cases of cHCC-CCA treated with atezolizumab plus bevacizumab. We observed three partial responses and one stable disease as the best responses; two of these patients were still being treated with atezolizumab plus bevacizumab at the time of reporting (at least five months of treatment), whereas the remaining two patients were unable to continue treatment owing to adverse events. Atezolizumab plus bevacizumab may be an effective treatment for unresectable cHCC-CCA.
肝内胆管癌合并肝细胞癌（cHCC-CCA）是原发性肝癌的一种罕见亚型。cHCC-CCA患者的治疗策略有限，对于不可切除的cHCC-CCA尚未确立标准的全身治疗方案。在此，我们报告6例接受阿替利珠单抗联合贝伐珠单抗治疗的cHCC-CCA患者。我们观察到3例部分缓解，1例病情稳定为最佳疗效；报告时，其中2例患者仍在接受阿替利珠单抗联合贝伐珠单抗治疗（至少治疗5个月），而其余2例患者因不良事件无法继续治疗。阿替利珠单抗联合贝伐珠单抗可能是不可切除cHCC-CCA的一种有效治疗方法。
